Make your own free website on
Home | 2003 (1997-2003) Cover Shorty | Inside cover | News 11-04 | News 6-04 | Current stock holdings | Election results | Stock from the company | Stock givers /traders | Profit and loss | Balance sheet 2003 | Balance sheet 2000 | RE, S&U, bank stmts 2003 | RE, S&U, bank stmts 2000 | News & history first half 2004 | Dr. Peebles' story | News & history 2001 - 2003 | News & history 1997 - 2000 | Owners like Pfizer strategy | Wal-Mart strategy | Pedi-sales strategy | Celgene takeover of pediatric drugs strategy | Device maker strategy | Your choice for licensing strategies | Ballot | Expenses graph | Expense report 2003 | Goodwill report 2003 | Contacts
Prophy Research Corporation reports
Your choice for licensing strategies

I’d like your opinion on the licensing strategies. You can just rank them (1 for your favorite), and/or make comments.

First and last name:
Are you a stockholder? (yes or no) (non-stockholders welcome to comment, too)
Owner strategy: Giving the owners of popular products like Tylenol the first option to license, at very low cost, for only their products.
Wal-mart strategy: Licensing our OptiDose to Wal-Mart to use on a new premium acetaminophen product to be priced higher than the current top brand (Tylenol®), yet have a cost about like their generic house brand.
Pedi-Sales strategy: Us selling droppers directly to pediatricians, to re-sell to their patients.
Celgene takeover pediatric drugs strategy: We give a broad license that will allow Celgene to sell all kinds of pediatric meds, OTC and Rx. Use dosing by weight as an exclusive feature to give pediatricians more business and therefore more recommendations to try our new versions of popular brands.
Device maker stategy: Licensing to the companies that manufacture and sell medicine droppers and such to the pharmaceutical companies.

On to the next page (a ballot - please vote if you are a stockholder)